Contrasting BioRestorative Therapies (BRTXQ) and Its Competitors

Earnings and Valuation

This table compares BioRestorative Therapies and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioRestorative Therapies	$110,000.00	-$12.52 million	-0.20
BioRestorative Therapies Competitors	$695.90 million	$9.91 million	-11.98

BioRestorative Therapies’ peers have higher revenue and earnings than BioRestorative Therapies. BioRestorative Therapies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

BioRestorative Therapies has a beta of 102.36, meaning that its share price is 10,136% more volatile than the S&P 500. Comparatively, BioRestorative Therapies’ peers have a beta of 1.25, meaning that their average share price is 25% more volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of shares of all “Biotechnology” companies are held by institutional investors. 12.2% of BioRestorative Therapies shares are held by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares BioRestorative Therapies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	N/A	N/A	N/A
BioRestorative Therapies Competitors	-9,375.31%	-127.87%	-33.50%

Summary

BioRestorative Therapies beats its peers on 5 of the 9 factors compared.

About BioRestorative Therapies

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company’s two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.